Your browser doesn't support javascript.
loading
Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.
Murhekar, Manoj V; Gupta, Nivedita; Hasan, Alvira Z; Kumar, Muthusamy Santhosh; Kumar, V Saravana; Prosperi, Christine; Sapkal, Gajanan N; Thangaraj, Jeromie Wesley Vivian; Kaduskar, Ojas; Bhatt, Vaishali; Deshpande, Gururaj Rao; Thankappan, Ullas Padinjaremattathil; Bansal, Avi Kumar; Chauhan, Sanjay L; Grover, Gangandeep Singh; Jain, Arun Kumar; Kulkarni, Ragini N; Sharma, Santanu Kumar; Chaaithanya, Itta K; Kharwal, Sanchit; Mishra, Sunil K; Salvi, Neha R; Sharma, Sandeep; Sarmah, Nilanju P; Sabarinathan, R; Duraiswamy, Augustine; Rani, D Sudha; Kanagasabai, K; Lachyan, Abhishek; Gawali, Poonam; Kapoor, Mitali; Shrivastava, Arpit Kumar; Chonker, Saurabh Kumar; Tilekar, Bipin; Tandale, Babasaheb V; Ahmad, Mohammad; Sangal, Lucky; Winter, Amy; Mehendale, Sanjay M; Moss, William J; Hayford, Kyla.
  • Murhekar MV; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India. Electronic address: mmurhekar@nieicmr.org.in.
  • Gupta N; Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi, India.
  • Hasan AZ; International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Kumar MS; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India.
  • Kumar VS; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India.
  • Prosperi C; International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Sapkal GN; ICMR-National Institute of Virology, Pune, India.
  • Thangaraj JWV; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India.
  • Kaduskar O; ICMR-National Institute of Virology, Pune, India.
  • Bhatt V; ICMR-National Institute of Virology, Pune, India.
  • Deshpande GR; ICMR-National Institute of Virology, Pune, India.
  • Thankappan UP; ICMR-National Institute of Virology, Pune, India.
  • Bansal AK; ICMR-National JALMA Institute for Leprosy & Other Mycobacterial Diseases, Agra, India.
  • Chauhan SL; ICMR- National Institute for Research in Reproductive and Child Health, Mumbai, India.
  • Grover GS; Directorate of Health Services, Government of Punjab, Chandigarh, India.
  • Jain AK; ICMR-National Institute of Pathology, New Delhi, India.
  • Kulkarni RN; ICMR- National Institute for Research in Reproductive and Child Health, Mumbai, India.
  • Sharma SK; ICMR-Regional Medical Research Centre, NE Region, Dibrugarh, India.
  • Chaaithanya IK; ICMR- National Institute for Research in Reproductive and Child Health, Mumbai, India; Department of Health Research, Model Rural Health Research Unit-Dahanu, Maharashtra, India.
  • Kharwal S; Department of Health Research, Model Rural Health Research Unit-Hoshiarpur, Punjab, India.
  • Mishra SK; Department of Health Research, Model Rural Health Research Unit-Hoshiarpur, Punjab, India.
  • Salvi NR; Department of Health Research, Model Rural Health Research Unit-Dahanu, Maharashtra, India.
  • Sharma S; ICMR-National JALMA Institute for Leprosy & Other Mycobacterial Diseases, Agra, India.
  • Sarmah NP; Department of Health Research, Model Rural Health Research Unit-Chabua, Assam, India.
  • Sabarinathan R; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India.
  • Duraiswamy A; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India.
  • Rani DS; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India.
  • Kanagasabai K; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India.
  • Lachyan A; Department of Health Research, Model Rural Health Research Unit-Dahanu, Maharashtra, India.
  • Gawali P; Department of Health Research, Model Rural Health Research Unit-Dahanu, Maharashtra, India.
  • Kapoor M; Department of Health Research, Model Rural Health Research Unit-Dahanu, Maharashtra, India.
  • Shrivastava AK; ICMR-National JALMA Institute for Leprosy & Other Mycobacterial Diseases, Agra, India.
  • Chonker SK; ICMR-National JALMA Institute for Leprosy & Other Mycobacterial Diseases, Agra, India.
  • Tilekar B; ICMR-National Institute of Virology, Pune, India.
  • Tandale BV; ICMR-National Institute of Virology, Pune, India.
  • Ahmad M; WHO Country Office, New Delhi, India.
  • Sangal L; WHO, Southeast Asia Region Office, New Delhi, India.
  • Winter A; International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Epidemiology and Statistics, University of Georgia, Athens, GA, USA.
  • Mehendale SM; PD Hinduja Hospital and Medical Research Centre, Mumbai, India.
  • Moss WJ; International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Hayford K; International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Lancet Glob Health ; 10(11): e1655-e1664, 2022 11.
Article en En | MEDLINE | ID: mdl-36240831
ABSTRACT

BACKGROUND:

India did phased measles-rubella supplementary immunisation activities (MR-SIAs; ie, mass-immunisation campaigns) targeting children aged 9 months to less than 15 years. We estimated measles-rubella seroprevalence before and after the MR-SIAs to quantify the effect on population immunity and identify remaining immunity gaps.

METHODS:

Between March 9, 2018 and March 19, 2020 we did community-based, cross-sectional serosurveys in four districts in India before and after MR-SIAs. 30 villages or wards were selected within each district, and one census enumeration block from each was selected as the survey cluster. Households were enumerated and 13 children in the younger age group (9 months to <5 years) and 13 children in the older ager group (5 to <15 years) were randomly selected by use of computer-generated random numbers. Serum samples were tested for IgG antibodies to measles and rubella viruses by enzyme immunoassay.

FINDINGS:

Specimens were collected from 2570 children before the MR-SIA and from 2619 children afterwards. The weighted MR-SIA coverage ranged from 73·7% to 90·5% in younger children and from 73·6% to 93·6% in older children. Before the MR-SIA, district-level measles seroprevalence was between 80·7% and 88·5% among younger children in all districts, and between 63·4% and 84·5% among older children. After the MR-SIA, measles seroprevalence among younger children increased to more than 90% (range 91·5 to 96·0) in all districts except Kanpur Nagar, in which it remained unchanged 80·4%. Among older children, measles seroprevalence increased to more than 90·0% (range 93·7% to 96·5%) in all districts except Hoshiarpur (88·7%). A significant increase in rubella seroprevalence was observed in all districts in both age groups, with the largest effect in Dibrugarh, where rubella seroprevalence increased from 10·6% to 96·5% among younger children.

INTERPRETATION:

Measles-rubella seroprevalence increased substantially after the MR-SIAs but the serosurvey also identified remaining gaps in population immunity.

FUNDING:

The Bill & Melinda Gates Foundation and Indian Council of Medical Research.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Rubéola (Sarampión Alemán) / Sarampión Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Child, preschool / Humans / Infant País como asunto: Asia Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Rubéola (Sarampión Alemán) / Sarampión Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Child, preschool / Humans / Infant País como asunto: Asia Idioma: En Año: 2022 Tipo del documento: Article